APO Research
Talk to an analyst

APO RESEARCH · REPORT

PCSK9 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global PCSK9 Inhibitors Industry Growth and Trends Forecast to 2032

20 December 2025106 pages

Choose your research edition.

Industry ResearchPCSK9 Inhibitors Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal PCSK9 Inhibitors Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal PCSK9 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PCSK9 Inhibitors Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal PCSK9 Inhibitors Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global PCSK9 Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for PCSK9 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for PCSK9 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PCSK9 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PCSK9 Inhibitors include Sanofi, Novartis, Merck, Roche, Eli Lilly, Pfizer, Daiichi Sankyo, Amgen and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global PCSK9 Inhibitors market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The PCSK9 Inhibitors market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global PCSK9 Inhibitors market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to PCSK9 Inhibitors.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global PCSK9 Inhibitors market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

PCSK9 Inhibitors Market by Company

Sanofi

Novartis

Merck

Roche

Eli Lilly

Pfizer

Daiichi Sankyo

Amgen

AstraZeneca

Ionis Pharmaceuticals

Cyon Therapeutics

BMS

Alnylam

Affiris

PCSK9 Inhibitors Segment by Type

Praluent(Alirocumab)

Bococizumab

Epatha(Evolocumab)

Others

PCSK9 Inhibitors Segment by Application

Clinical Application

Drug Development

Other

PCSK9 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PCSK9 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PCSK9 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PCSK9 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PCSK9 Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of PCSK9 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Praluent(Alirocumab) Table 2. Major Company of Bococizumab Table 3. Major Company of Epatha(Evolocumab) Table 4. Major Company of Others Table 5. Global PCSK9 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global PCSK9 Inhibitors Sales by Type (2021-2026) & (k units) Table 7. Global PCSK9 Inhibitors Sales Market Share in Volume by Type (2021-2026) Table 8. Global PCSK9 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 9. Global PCSK9 Inhibitors Sales Market Share in Value by Type (2021-2026) Table 10. Global PCSK9 Inhibitors Price by Type (2021-2026) & (US$/unit) Table 11. Global PCSK9 Inhibitors Sales by Type (2027-2032) & (k units) Table 12. Global PCSK9 Inhibitors Sales Market Share in Volume by Type (2027-2032) Table 13. Global PCSK9 Inhibitors Sales by Type (2027-2032) & (US$ Million) Table 14. Global PCSK9 Inhibitors Sales Market Share in Value by Type (2027-2032) Table 15. Global PCSK9 Inhibitors Price by Type (2027-2032) & (US$/unit) Table 16. North America PCSK9 Inhibitors Sales by Type (2021-2026) & (k units) Table 17. North America PCSK9 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 18. Europe PCSK9 Inhibitors Sales by Type (2021-2026) & (k units) Table 19. Europe PCSK9 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific PCSK9 Inhibitors Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific PCSK9 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America PCSK9 Inhibitors Sales by Type (2021-2026) & (k units) Table 23. Latin America PCSK9 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa PCSK9 Inhibitors Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa PCSK9 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 26. PCSK9 Inhibitors Industry Trends Table 27. PCSK9 Inhibitors Industry Drivers Table 28. PCSK9 Inhibitors Industry Opportunities and Challenges Table 29. PCSK9 Inhibitors Industry Restraints Table 30. Global PCSK9 Inhibitors Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global PCSK9 Inhibitors Revenue Market Share by Company (2021-2026) Table 32. Global PCSK9 Inhibitors Sales by Company (2021-2026) & (k units) Table 33. Global PCSK9 Inhibitors Sales Share by Company (2021-2026) Table 34. Global PCSK9 Inhibitors Market Price by Company (2021-2026) & (US$/unit) Table 35. Global PCSK9 Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global PCSK9 Inhibitors Major Company Production Sites and Headquarters Table 37. Global PCSK9 Inhibitors Company, Product Type & Application Table 38. Global PCSK9 Inhibitors Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global PCSK9 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global PCSK9 Inhibitors Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global PCSK9 Inhibitors Sales by Region (2021-2026) & (k units) Table 43. Global PCSK9 Inhibitors Sales Market Share in Volume by Region (2021-2026) Table 44. Global PCSK9 Inhibitors Sales by Region (2021-2026) & (US$ Million) Table 45. Global PCSK9 Inhibitors Sales Market Share in Value by Region (2021-2026) Table 46. Global PCSK9 Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global PCSK9 Inhibitors Sales by Region (2027-2032) & (k units) Table 48. Global PCSK9 Inhibitors Sales Market Share in Volume by Region (2027-2032) Table 49. Global PCSK9 Inhibitors Sales by Region (2027-2032) & (US$ Million) Table 50. Global PCSK9 Inhibitors Sales Market Share in Value by Region (2027-2032) Table 51. Global PCSK9 Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global PCSK9 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global PCSK9 Inhibitors Sales by Application (2021-2026) & (k units) Table 54. Global PCSK9 Inhibitors Sales Market Share in Volume by Application (2021-2026) Table 55. Global PCSK9 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 56. Global PCSK9 Inhibitors Sales Market Share in Value by Application (2021-2026) Table 57. Global PCSK9 Inhibitors Price by Application (2021-2026) & (US$/unit) Table 58. Global PCSK9 Inhibitors Sales by Application (2027-2032) & (k units) Table 59. Global PCSK9 Inhibitors Sales Market Share in Volume by Application (2027-2032) Table 60. Global PCSK9 Inhibitors Sales by Application (2027-2032) & (US$ Million) Table 61. Global PCSK9 Inhibitors Sales Market Share in Value by Application (2027-2032) Table 62. Global PCSK9 Inhibitors Price by Application (2027-2032) & (US$/unit) Table 63. North America PCSK9 Inhibitors Sales by Application (2021-2026) & (k units) Table 64. North America PCSK9 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 65. Europe PCSK9 Inhibitors Sales by Application (2021-2026) & (k units) Table 66. Europe PCSK9 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific PCSK9 Inhibitors Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific PCSK9 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America PCSK9 Inhibitors Sales by Application (2021-2026) & (k units) Table 70. Latin America PCSK9 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa PCSK9 Inhibitors Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa PCSK9 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Sanofi PCSK9 Inhibitors Product Portfolio Table 77. Sanofi Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Novartis PCSK9 Inhibitors Product Portfolio Table 82. Novartis Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Merck PCSK9 Inhibitors Product Portfolio Table 87. Merck Recent Development Table 88. Roche Company Information Table 89. Roche Business Overview Table 90. Roche PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Roche PCSK9 Inhibitors Product Portfolio Table 92. Roche Recent Development Table 93. Eli Lilly Company Information Table 94. Eli Lilly Business Overview Table 95. Eli Lilly PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Eli Lilly PCSK9 Inhibitors Product Portfolio Table 97. Eli Lilly Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Pfizer PCSK9 Inhibitors Product Portfolio Table 102. Pfizer Recent Development Table 103. Daiichi Sankyo Company Information Table 104. Daiichi Sankyo Business Overview Table 105. Daiichi Sankyo PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Daiichi Sankyo PCSK9 Inhibitors Product Portfolio Table 107. Daiichi Sankyo Recent Development Table 108. Amgen Company Information Table 109. Amgen Business Overview Table 110. Amgen PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Amgen PCSK9 Inhibitors Product Portfolio Table 112. Amgen Recent Development Table 113. AstraZeneca Company Information Table 114. AstraZeneca Business Overview Table 115. AstraZeneca PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. AstraZeneca PCSK9 Inhibitors Product Portfolio Table 117. AstraZeneca Recent Development Table 118. Ionis Pharmaceuticals Company Information Table 119. Ionis Pharmaceuticals Business Overview Table 120. Ionis Pharmaceuticals PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Ionis Pharmaceuticals PCSK9 Inhibitors Product Portfolio Table 122. Ionis Pharmaceuticals Recent Development Table 123. Cyon Therapeutics Company Information Table 124. Cyon Therapeutics Business Overview Table 125. Cyon Therapeutics PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Cyon Therapeutics PCSK9 Inhibitors Product Portfolio Table 127. Cyon Therapeutics Recent Development Table 128. BMS Company Information Table 129. BMS Business Overview Table 130. BMS PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. BMS PCSK9 Inhibitors Product Portfolio Table 132. BMS Recent Development Table 133. Alnylam Company Information Table 134. Alnylam Business Overview Table 135. Alnylam PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Alnylam PCSK9 Inhibitors Product Portfolio Table 137. Alnylam Recent Development Table 138. Affiris Company Information Table 139. Affiris Business Overview Table 140. Affiris PCSK9 Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Affiris PCSK9 Inhibitors Product Portfolio Table 142. Affiris Recent Development Table 143. North America PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 144. North America PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 145. North America PCSK9 Inhibitors Sales Market Share by Country (2021-2026) Table 146. North America PCSK9 Inhibitors Sales Forecast by Country (2027-2032) & (k units) Table 147. North America PCSK9 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 148. North America PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America PCSK9 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 150. North America PCSK9 Inhibitors Market Share by Country (2021-2026) Table 151. North America PCSK9 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America PCSK9 Inhibitors Market Share Forecast by Country (2027-2032) Table 153. Europe PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 154. Europe PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 155. Europe PCSK9 Inhibitors Sales Market Share by Country (2021-2026) Table 156. Europe PCSK9 Inhibitors Sales Forecast by Country (2027-2032) & (k units) Table 157. Europe PCSK9 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 158. Europe PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Europe PCSK9 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 160. Europe PCSK9 Inhibitors Market Share by Country (2021-2026) Table 161. Europe PCSK9 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Europe PCSK9 Inhibitors Market Share Forecast by Country (2027-2032) Table 163. Asia-Pacific PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 164. Asia-Pacific PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 165. Asia-Pacific PCSK9 Inhibitors Sales Market Share by Country (2021-2026) Table 166. Asia-Pacific PCSK9 Inhibitors Sales Forecast by Country (2027-2032) & (k units) Table 167. Asia-Pacific PCSK9 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific PCSK9 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 170. Asia-Pacific PCSK9 Inhibitors Market Share by Country (2021-2026) Table 171. Asia-Pacific PCSK9 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Asia-Pacific PCSK9 Inhibitors Market Share Forecast by Country (2027-2032) Table 173. Latin America PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 174. Latin America PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 175. Latin America PCSK9 Inhibitors Sales Market Share by Country (2021-2026) Table 176. Latin America PCSK9 Inhibitors Sales Forecast by Country (2027-2032) & (k units) Table 177. Latin America PCSK9 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 178. Latin America PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Latin America PCSK9 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 180. Latin America PCSK9 Inhibitors Market Share by Country (2021-2026) Table 181. Latin America PCSK9 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Latin America PCSK9 Inhibitors Market Share Forecast by Country (2027-2032) Table 183. Middle East and Africa PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 184. Middle East and Africa PCSK9 Inhibitors Sales by Country (2021-2026) & (k units) Table 185. Middle East and Africa PCSK9 Inhibitors Sales Market Share by Country (2021-2026) Table 186. Middle East and Africa PCSK9 Inhibitors Sales Forecast by Country (2027-2032) & (k units) Table 187. Middle East and Africa PCSK9 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 188. Middle East and Africa PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Middle East and Africa PCSK9 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 190. Middle East and Africa PCSK9 Inhibitors Market Share by Country (2021-2026) Table 191. Middle East and Africa PCSK9 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Middle East and Africa PCSK9 Inhibitors Market Share Forecast by Country (2027-2032) Table 193. Key Raw Materials Table 194. Raw Materials Key Suppliers Table 195. PCSK9 Inhibitors Distributors List Table 196. PCSK9 Inhibitors Customers List Table 197. Research Programs/Design for This Report Table 198. Authors List of This Report Table 199. Secondary Sources Table 200. Primary Sources List of Figures Figure 1. PCSK9 Inhibitors Image Figure 2. Global PCSK9 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PCSK9 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global PCSK9 Inhibitors Sales (2021-2032) & (k units) Figure 5. Praluent(Alirocumab) Image Figure 6. Global Praluent(Alirocumab) Sales YoY Growth (2021-2032) & (k units) Figure 7. Bococizumab Image Figure 8. Global Bococizumab Sales YoY Growth (2021-2032) & (k units) Figure 9. Epatha(Evolocumab) Image Figure 10. Global Epatha(Evolocumab) Sales YoY Growth (2021-2032) & (k units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 13. Global PCSK9 Inhibitors Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global PCSK9 Inhibitors Market Share by Type 2025 VS 2032 Figure 15. North America PCSK9 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 16. North America PCSK9 Inhibitors Sales Market Share in Value by Type in 2025 Figure 17. Europe PCSK9 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 18. Europe PCSK9 Inhibitors Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Value by Type in 2025 Figure 21. Latin America PCSK9 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 22. Latin America PCSK9 Inhibitors Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 PCSK9 Inhibitors Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Clinical Application Image Figure 28. Global Clinical Application Sales YoY Growth (2021-2032) & (k units) Figure 29. Drug Development Image Figure 30. Global Drug Development Sales YoY Growth (2021-2032) & (k units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 33. Global PCSK9 Inhibitors Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global PCSK9 Inhibitors Market Share by Application 2025 VS 2032 Figure 35. North America PCSK9 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 36. North America PCSK9 Inhibitors Sales Market Share in Value by Application in 2025 Figure 37. Europe PCSK9 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 38. Europe PCSK9 Inhibitors Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Value by Application in 2025 Figure 41. Latin America PCSK9 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 42. Latin America PCSK9 Inhibitors Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Value by Application in 2025 Figure 45. North America PCSK9 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America PCSK9 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America PCSK9 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America PCSK9 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe PCSK9 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe PCSK9 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe PCSK9 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe PCSK9 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific PCSK9 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific PCSK9 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific PCSK9 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific PCSK9 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America PCSK9 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America PCSK9 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America PCSK9 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America PCSK9 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa PCSK9 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa PCSK9 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa PCSK9 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa PCSK9 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. PCSK9 Inhibitors Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. PCSK9 Inhibitors Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Praluent(Alirocumab)
  • Bococizumab
  • Epatha(Evolocumab)
  • Others
Applications
  • Clinical Application
  • Drug Development
  • Other
Companies covered
  • Sanofi
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Daiichi Sankyo
  • Amgen
  • AstraZeneca
  • Ionis Pharmaceuticals
  • Cyon Therapeutics
  • BMS
  • Alnylam
  • Affiris

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PCSK9 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global PCSK9 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.3 PCSK9 Inhibitors Market by Type
  6. 1.3.1 Praluent(Alirocumab)
  7. 1.3.2 Bococizumab
  8. 1.3.3 Epatha(Evolocumab)
  9. 1.3.4 Others
  10. 1.4 Global PCSK9 Inhibitors Market Size by Type
  11. 1.4.1 Global PCSK9 Inhibitors Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global PCSK9 Inhibitors Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global PCSK9 Inhibitors Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America PCSK9 Inhibitors Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe PCSK9 Inhibitors Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific PCSK9 Inhibitors Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America PCSK9 Inhibitors Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa PCSK9 Inhibitors Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 PCSK9 Inhibitors Industry Trends
  2. 2.2 PCSK9 Inhibitors Industry Drivers
  3. 2.3 PCSK9 Inhibitors Industry Opportunities and Challenges
  4. 2.4 PCSK9 Inhibitors Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by PCSK9 Inhibitors Revenue (2021-2026)
  2. 3.2 Global Top Players by PCSK9 Inhibitors Sales (2021-2026)
  3. 3.3 Global Top Players by PCSK9 Inhibitors Price (2021-2026)
  4. 3.4 Global PCSK9 Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PCSK9 Inhibitors Major Company Production Sites & Headquarters
  6. 3.6 Global PCSK9 Inhibitors Company, Product Type & Application
  7. 3.7 Global PCSK9 Inhibitors Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PCSK9 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PCSK9 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PCSK9 Inhibitors Tier 1, Tier 2, and Tier 3
4 PCSK9 Inhibitors Regional Status and Outlook
  1. 4.1 Global PCSK9 Inhibitors Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global PCSK9 Inhibitors Historic Market Size by Region
  3. 4.2.1 Global PCSK9 Inhibitors Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global PCSK9 Inhibitors Sales in Value by Region (2021-2026)
  5. 4.2.3 Global PCSK9 Inhibitors Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global PCSK9 Inhibitors Forecasted Market Size by Region
  7. 4.3.1 Global PCSK9 Inhibitors Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global PCSK9 Inhibitors Sales in Value by Region (2027-2032)
  9. 4.3.3 Global PCSK9 Inhibitors Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 PCSK9 Inhibitors by Application
  1. 5.1 PCSK9 Inhibitors Market by Application
  2. 5.1.1 Clinical Application
  3. 5.1.2 Drug Development
  4. 5.1.3 Other
  5. 5.2 Global PCSK9 Inhibitors Market Size by Application
  6. 5.2.1 Global PCSK9 Inhibitors Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global PCSK9 Inhibitors Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global PCSK9 Inhibitors Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America PCSK9 Inhibitors Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe PCSK9 Inhibitors Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific PCSK9 Inhibitors Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America PCSK9 Inhibitors Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa PCSK9 Inhibitors Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi PCSK9 Inhibitors Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis PCSK9 Inhibitors Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck PCSK9 Inhibitors Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Roche
  20. 6.4.1 Roche Company Information
  21. 6.4.2 Roche Business Overview
  22. 6.4.3 Roche PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Roche PCSK9 Inhibitors Product Portfolio
  24. 6.4.5 Roche Recent Developments
  25. 6.5 Eli Lilly
  26. 6.5.1 Eli Lilly Company Information
  27. 6.5.2 Eli Lilly Business Overview
  28. 6.5.3 Eli Lilly PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Eli Lilly PCSK9 Inhibitors Product Portfolio
  30. 6.5.5 Eli Lilly Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer PCSK9 Inhibitors Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Daiichi Sankyo
  38. 6.7.1 Daiichi Sankyo Company Information
  39. 6.7.2 Daiichi Sankyo Business Overview
  40. 6.7.3 Daiichi Sankyo PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Daiichi Sankyo PCSK9 Inhibitors Product Portfolio
  42. 6.7.5 Daiichi Sankyo Recent Developments
  43. 6.8 Amgen
  44. 6.8.1 Amgen Company Information
  45. 6.8.2 Amgen Business Overview
  46. 6.8.3 Amgen PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Amgen PCSK9 Inhibitors Product Portfolio
  48. 6.8.5 Amgen Recent Developments
  49. 6.9 AstraZeneca
  50. 6.9.1 AstraZeneca Company Information
  51. 6.9.2 AstraZeneca Business Overview
  52. 6.9.3 AstraZeneca PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 AstraZeneca PCSK9 Inhibitors Product Portfolio
  54. 6.9.5 AstraZeneca Recent Developments
  55. 6.10 Ionis Pharmaceuticals
  56. 6.10.1 Ionis Pharmaceuticals Company Information
  57. 6.10.2 Ionis Pharmaceuticals Business Overview
  58. 6.10.3 Ionis Pharmaceuticals PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Ionis Pharmaceuticals PCSK9 Inhibitors Product Portfolio
  60. 6.10.5 Ionis Pharmaceuticals Recent Developments
  61. 6.11 Cyon Therapeutics
  62. 6.11.1 Cyon Therapeutics Company Information
  63. 6.11.2 Cyon Therapeutics Business Overview
  64. 6.11.3 Cyon Therapeutics PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Cyon Therapeutics PCSK9 Inhibitors Product Portfolio
  66. 6.11.5 Cyon Therapeutics Recent Developments
  67. 6.12 BMS
  68. 6.12.1 BMS Company Information
  69. 6.12.2 BMS Business Overview
  70. 6.12.3 BMS PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 BMS PCSK9 Inhibitors Product Portfolio
  72. 6.12.5 BMS Recent Developments
  73. 6.13 Alnylam
  74. 6.13.1 Alnylam Company Information
  75. 6.13.2 Alnylam Business Overview
  76. 6.13.3 Alnylam PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Alnylam PCSK9 Inhibitors Product Portfolio
  78. 6.13.5 Alnylam Recent Developments
  79. 6.14 Affiris
  80. 6.14.1 Affiris Company Information
  81. 6.14.2 Affiris Business Overview
  82. 6.14.3 Affiris PCSK9 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Affiris PCSK9 Inhibitors Product Portfolio
  84. 6.14.5 Affiris Recent Developments
7 North America by Country
  1. 7.1 North America PCSK9 Inhibitors Sales by Country
  2. 7.1.1 North America PCSK9 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America PCSK9 Inhibitors Sales by Country (2021-2026)
  4. 7.1.3 North America PCSK9 Inhibitors Sales Forecast by Country (2027-2032)
  5. 7.2 North America PCSK9 Inhibitors Market Size by Country
  6. 7.2.1 North America PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America PCSK9 Inhibitors Market Size by Country (2021-2026)
  8. 7.2.3 North America PCSK9 Inhibitors Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe PCSK9 Inhibitors Sales by Country
  2. 8.1.1 Europe PCSK9 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe PCSK9 Inhibitors Sales by Country (2021-2026)
  4. 8.1.3 Europe PCSK9 Inhibitors Sales Forecast by Country (2027-2032)
  5. 8.2 Europe PCSK9 Inhibitors Market Size by Country
  6. 8.2.1 Europe PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe PCSK9 Inhibitors Market Size by Country (2021-2026)
  8. 8.2.3 Europe PCSK9 Inhibitors Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific PCSK9 Inhibitors Sales by Country
  2. 9.1.1 Asia-Pacific PCSK9 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific PCSK9 Inhibitors Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific PCSK9 Inhibitors Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific PCSK9 Inhibitors Market Size by Country
  6. 9.2.1 Asia-Pacific PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific PCSK9 Inhibitors Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific PCSK9 Inhibitors Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America PCSK9 Inhibitors Sales by Country
  2. 10.1.1 South America PCSK9 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America PCSK9 Inhibitors Sales by Country (2021-2026)
  4. 10.1.3 South America PCSK9 Inhibitors Sales Forecast by Country (2027-2032)
  5. 10.2 South America PCSK9 Inhibitors Market Size by Country
  6. 10.2.1 South America PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America PCSK9 Inhibitors Market Size by Country (2021-2026)
  8. 10.2.3 South America PCSK9 Inhibitors Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa PCSK9 Inhibitors Sales by Country
  2. 11.1.1 Middle East and Africa PCSK9 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa PCSK9 Inhibitors Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa PCSK9 Inhibitors Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa PCSK9 Inhibitors Market Size by Country
  6. 11.2.1 Middle East and Africa PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa PCSK9 Inhibitors Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa PCSK9 Inhibitors Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 PCSK9 Inhibitors Value Chain Analysis
  2. 12.1.1 PCSK9 Inhibitors Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 PCSK9 Inhibitors Production Mode & Process
  7. 12.2 PCSK9 Inhibitors Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 PCSK9 Inhibitors Distributors
  10. 12.2.3 PCSK9 Inhibitors Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst